- Latest available (Revised)
- Point in Time (01/04/2010)
- Original (As made)
There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
PART 4 Capital Fees for Assistance in Obtaining Marketing Authorizations in Other EEA States
PART 9 Capital Fees for Inspections
28.Payer of inspection fee (contract laboratories and API manufacturing sites)
30.Fees for inspections relating to good clinical practice in clinical trials
31.Amount of and time for payment of inspection fees in respect of an application for a wholesale dealer's licence
32.Adjustment and refund of inspection fees in respect of a wholesale dealer's licence
PART 10 Periodic Fees for Marketing Authorizations and Licences
PART 1 General: interpretation and categories of applications and variations
PART 2 Capital Fees for Applications for Authorizations, Licences, Registrations and Certificates
PART 3 Capital Fees for Assistance in Obtaining Marketing Authorizations in Other EEA States
PART 4 Capital Fees for Applications for Variations of Authorizations, Licences and Registrations
38.Variation of marketing authorization: national homoeopathic products
46A.Reduced fees for Type IB and Type II Applications, Minor Variation (Type IB) Group Applications and a Major Variation (Type II) Group Applications
47A.Reduced Fees for identical Type II Complex Applications, Extended Type II Complex Variation Applications, Major Variation (Type II) Complex Group Applications and Major Variation (Type II) Extended Complex Group Applications
WAIVER, REDUCTION OR REFUND OF CAPITAL FEES
4.Withdrawal of application in relation to marketing authorization, traditional herbal registration or clinical trial authorisation
5.Withdrawal of application in relation to manufacturing authorisation, wholesale dealer's or manufacturer's licence
6.Refusal of application for grant of marketing authorization, traditional herbal registration or clinical trial authorisation
8.Surrender of marketing authorization at same time as a variation application
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: